Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon: A Randomized Clinical Trial.

Tytuł :
Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon: A Randomized Clinical Trial.
Autorzy :
Sani HD; Atherosclerosis Prevention Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Eshraghi A; Atherosclerosis Prevention Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Nezafati MH; Department of Cardiac Surgery, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Vojdanparast M; Atherosclerosis Prevention Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Shahri B; Atherosclerosis Prevention Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Nezafati P; Department of Cardiac Surgery, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran .
Pokaż więcej
Źródło :
Journal of cardiovascular pharmacology and therapeutics [J Cardiovasc Pharmacol Ther] 2015 Jul; Vol. 20 (4), pp. 401-6. Date of Electronic Publication: 2015 Feb 20.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial
Język :
English
Imprint Name(s) :
Publication: 2007- : Thousand Oaks, Calif. : Sage Publications
Original Publication: Naperville, IL : Churchill Livingstone Inc., c1996-
MeSH Terms :
Angina Pectoris/*drug therapy
Nicorandil/*therapeutic use
Nitroglycerin/*therapeutic use
No-Reflow Phenomenon/*drug therapy
Adult ; Aged ; Canada ; Coronary Angiography ; Delayed-Action Preparations ; Female ; Humans ; Male ; Middle Aged ; Single-Blind Method ; Treatment Outcome ; Vasodilator Agents/therapeutic use
Contributed Indexing :
Keywords: angina pectoris/drug therapy; blood flow velocity/drug effects; nicorandil/administration and dosage; nitroglycerin/administration and dosage; randomized controlled trial; treatment outcome
Substance Nomenclature :
0 (Delayed-Action Preparations)
0 (Vasodilator Agents)
260456HAM0 (Nicorandil)
G59M7S0WS3 (Nitroglycerin)
Entry Date(s) :
Date Created: 20150222 Date Completed: 20160321 Latest Revision: 20150618
Update Code :
20210210
DOI :
10.1177/1074248415571457
PMID :
25701829
Czasopismo naukowe
Objective: Patients with the coronary slow flow phenomenon frequently experience angina episodes. The present study aimed to compare the efficacy of nicorandil versus nitroglycerin for alleviation of angina symptoms in slow flow patients.
Methods: In a single-center, single-blind, parallel-design, comparator-controlled, randomized clinical trial (NCT02254252), 54 patients with slow flow and normal or near-normal coronary angiography who presented with frequent angina episodes were randomly assigned to 1-month treatment with nicorandil 10 mg, 2 times a day (n = 27) or sustained-release glyceryltrinitrate 6.4 mg 2 times a day (n =27). Frequency of angina episodes, pain intensity, and the Canadian Cardiovascular Society (CCS) grading of angina pectoris were assessed at baseline and after 1 month of treatment.
Results: In all, 25 patients in the nicorandil arm and 24 patients in the nitroglycerin arm were analyzed. After 1 month, patients treated with nicorandil had fewer angina episodes (adjusted mean number of episodes per week, nicorandil versus nitroglycerin; 1.68 ± 0.15 vs 2.29 ± 0.15, P = .007, effect size = 14.6%). Patients also reported greater reductions in pain intensity with nicorandil versus nitroglycerin (adjusted mean of self-reported pain score; 3.03 ± 0.29 vs 3.89 ± 0.30, P = .046, effect size = 8.4%). A significantly higher proportion of patients in the nicorandil arm were categorized in CCS class I (76% vs 33.3%, P = .004) or class II (16.0% vs 45.8%, P = .032).
Conclusion: In slow flow patients, nicorandil provides better symptomatic relief of angina than nitroglycerin.
(© The Author(s) 2015.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies